Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

4

Revenue 2017

Herceptin

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Herceptin was produced by Roche.

A new decade of disruption: meeting the biosimilar challgenge

A new decade of disruption: meeting the biosimilar challgenge An example can be seen in Roche’s introduction of an injectable alternative to its intravenous formulation of Herceptin (trastuzumab) in 2013 before the drug lost exclusivity in Europe.

Mylan deal with Roche clears path to biosimilar Herceptin launch

Mylan deal with Roche clears path to biosimilar Herceptin launch being the first company to launch a biosimilar to Herceptin in the US". ... two companies have already launched their copycat Herceptin in 14 emerging markets, including India.

2016: The year when deal-makers took stock?

2016: The year when deal-makers took stock? Canada for biosimilar versions of Rituxan (rituximab) and Herceptin (trastuzumab). .

Genentech names Anderson new CEO as Ian Clark retires

Genentech names Anderson new CEO as Ian Clark retires Big-selling brands such as breast cancer therapy Herceptin (trastuzumab), Avastin (bevacizumab) for solid tumours and MabThera/Rituxan (rituximab) for non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are

NICE backs Roche’s Perjeta for routine NHS use

NICE backs Roche’s Perjeta for routine NHS use Given in combination with Herceptin (trastuzumab) and docetaxel, Perjeta (pertuzumab) was recommended to treat women with HER2-positive, locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence. ... preparation for surgery

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics